Yup. Regardless of what the "market" says, today

Yup. Regardless of what the "market" says, today news could not be better.

The street has gotten used to earth-shaking news and ignoring them. ANY other company would had jumped double-digits in % terms. Simply because we got confirmation from a second patient and sustained therapeutic benefits in the first one (undetectable levels of CTCs after 11 weeks).

So be it, they are doing it at their own peril. The problem is, we don't have institucional investors, so the price goes up and down at the whims of few retail investors with short (an myopic) objectives.

However, for those who want to hear, want to see and can add:

Quote:

---

Aug 19, 2019 Breast cancer therapeutics market has gained an appreciable popularity over the past few years with the advent of novel drugs addressing specific actionable targets. The commercialization potential of the industry is quite evident from the estimates depicted by Global Market Insights Inc., that claims that breast cancer therapeutics market size to exceed a valuation of USD 28 billion by 2024, primarily backed by the increasing patient pool suffering from breast cancer. Statistics depict, worldwide, incidence of breast cancer has witnessed a tremendous surge over the recent years, with an estimated figure of almost 1.7 million new cases being diagnosed yearly. In fact, as per WHO's updated report of 2015, approximately 520,000 casualties result from breast cancer every year. The aforementioned figures itself are testimony to the huge opportunities that breast cancer therapeutics market is yet to unfold.

Breast Cancer Therapeutics Market size was valued over USD 16,228.2 million in 2018 and is expected to witness 9.5% CAGR from 2019 to 2025.

---

So we are currently at around $18 Billion market. Make your calculations with any penetration numbers you want … I don't want to propose any number as will be accused of having way too many Buchanans in the Holiday Spirit

Let me just say: the SP will be astronomical once Lero is approved for BC regardless of the market penetration.